Results 91 to 100 of about 54,010 (241)
Cancer Treatment and Research CommunicationsPurpose: There is evidence that adding cetuximab can overcome resistance to irinotecan, but a similar analysis with Panitumumab isn't readily available. This study evaluated the activity of each anti-EGFR plus irinotecan as a salvage third-line treatment
Maria Ignez Freitas Melro Braghiroli +13 more
doaj +1 more source
Voltammetric Characterisation of Anticancer Drug Irinotecan
, 2017 Electrochemical reduction of irinotecan was investigated on a static mercury drop electrode using square-wave voltammetry. The mechanism of irinotecan electroreduction is a complex, pH-dependent, quasireversible process and includes the transfer of two ...
Jovanović-Novak, Ivana +9 more
core +1 more source
Asia-Pacific Journal of Clinical Oncology, EarlyView.There is limited understanding of the impact of underlying RAS/RAF mutational status on total neoadjuvant therapy metastatic tumor response rates in curative Stage IV rectal cancer patients. Complete metastatic tumor response to TNT was demonstrated in half as many mRAS as wtRAS patients and disease progression was higher in patients harboring RAS ...
Tracy R. Fitzsimmons +8 more
wiley +1 more source
Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview
, 2001 PURPOSE AND METHODS: For more than three decades, the therapeutic options for patients with advanced colorectal cancer have almost exclusively been based on fluoropyrimidines. With the recognition that topoisomerase-I (TOP-I) is an important therapeutic
Wolf Achterrath +5 more
core +1 more source
Rifaximin alleviates irinotecan-induced diarrhea in mice model
Annals of MedicineBackground Irinotecan is a chemotherapeutic drug widely used to treat solid tumors. However, its effectiveness is limited by the severely delayed onset of diarrhea.
Chengyi Huang +9 more
doaj +1 more source
British Journal of Pharmacology, EarlyView.Background and purpose Nano‐formulated chemotherapeutics prolong systemic availability of drugs and can reduce systemic toxicity, but their accumulation in solid tumours is often limited and unpredictable. Broadly applicable strategies to selectively enhance tumour delivery are lacking.
Annabel Kitowski +13 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Genomic profiling of patients for genetic variants that modify the effect of specific medications has many benefits, including the possibility of avoiding toxicities and ensuring an adequate effect of the medication. Our intention was to develop a comprehensive, high‐quality pharmacogenetic test panel for clinical use ...
Anna Gréen +5 more
wiley +1 more source
Response of small intestinal epithelial cells to irinotecan.
, 2013 (A) Significant decrease in the number of BrdU postive cells in the small intestinal crypts of irinotecan-treated mice. WT mice were injected with PBS (cont) or irinotecan (CPT) for 6 consecutive days and sacrificed on day 7. One hour prior to sacrifice,
Helen Piwnica-Worms (251639) +5 more
core +1 more source
Semi-physiological model of irinotecan PK.
, 2020 Compartments were minimised to the most important components, Liver to accurately represent drug delivery, Blood which is measurement site and Organs to represent the rest of the body. Ci is the rate constant of clearance from compartment i.
Roger J. W. Hill (8363451) +3 more
core +1 more source
British Journal of Pharmacology, EarlyView.Abstract Aim Fluoropyrimidines, including 5‐fluorouracil (5‐FU) and capecitabine, are cornerstone antineoplastic agents for cancer. Case reports suggest that these drugs may be associated with an under‐recognised risk of ischaemic stroke or transient ischaemic attack (TIA).
Sophie Nguyen +12 more
wiley +1 more source